Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study

Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study

Objective: to compare the efficacy and tolerability of second‑line chemotherapy with original bevacizumab (Avastin) and biosimilar bevacizumab produced by “Biocad” (Avegra) in patients with metastatic colon cancer.Materials and methods. This retrospective observational study included patients with m...

Full description

Bibliographic Details
Main Authors: M.   Yu. Fedyanin, F.   V. Moiseenko, M.   A. Lyadova, V.  N.  Vorobyeva, V.  V.  Petkau, A.  V.  Fateeva, E.  S.  Kuzmina, O.  Yu.  Novikova, V.   A. Chubenko, N.  Kh.  Abduloeva, A.  A.  Kudryavtsev, E.   O. Ignatova, R.   R. Shakirov, O.  A.  Pardabekova, L.  V.  Kindyalova, S.  P.  Pelikh, O.   A. Gladkov, S.  A.  Tjulandin, A.  A.  Tryakin
Format: Article
Language:Russian
Published: “ABV-press” Publishing house”, LLC 2021-06-01
Series:Тазовая хирургия и онкология
Subjects:
colon cancer
antiangiogenic therapy
biosimilars
bevacizumab
avastin
Online Access:https://ok.abvpress.ru/jour/article/view/491

Internet

https://ok.abvpress.ru/jour/article/view/491

Similar Items